알테오젠

196170KOSDAQ

63.0 / 100

Reference Date: 2026-10-23

Financial Score28.5 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 10.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Alteogen is a biotech company leveraging platform technologies like Hybrozyme™, NexP™, and NexMab™ to develop and commercialize biopharmaceuticals, with licensing agreements with global pharma firms such as MSD and AstraZeneca, ensuring sustainable revenue through upfront fees, milestones, and royalties. Its key product ALT-B4 offers subcutaneous injection advantages over IV formulations, while its biosimilar business collaborates with Qilu Pharmaceutical to expand market reach.

Number of Employees

161people

Average Salary

149.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

86.69Industry Average 15.000.0Point

5.8x industry avg (risky)

PBR

—Industry Average 1.203.5Point

ROE

39.85Industry Average 8.007.0Point

5.0x industry avg (excellent)

Debt Ratio

1.02Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~202510.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲58.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲340.9% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 22.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 230,000Won52-week high 559,00052-week low 208,000

1-month return1.0Point

1m -10.33% (falling)

Volume trend5.0Point

Volume flat

Detailed Disclosure

12 totalPositive 4Neutral 8Negative 0

Neutral[기재정정]증권신고서(합병)2026-10-19
Neutral증권발행결과(자율공시)2026-10-14
Neutral증권발행결과(자율공시)2026-10-14
Neutral증권신고서(합병)2026-10-14
Neutral기업설명회(IR)개최2026-10-08